Market Overview

Pfizer Confirms License of Families of Spinal Muscular Atrophy Quinazoline Drug Program from Repligen

Share:
Related RGEN
Mid-Afternoon Market Update: Stage Stores Drops On Downbeat Results; Urban Outfitters Shares Surge
Benzinga's M&A Chatter for Monday April 4, 2016
Related PFE
Pfizer And Western Oncolytics Reach Immuno-Oncology Research Collaboration
18 Biggest Mid-Day Gainers For Wednesday
Apple Tops Dogs Of The Dow July Analysis (Seeking Alpha)

Repligen Corporation (NASDAQ: RGEN) announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. (NYSE: PFE) to advance Repligen's spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA).

Posted-In: News FDA

 

Related Articles (RGEN + PFE)

View Comments and Join the Discussion!